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ABSTRACT
Aims and background. Anthracyclines such as doxorubicin play a central role in the
management of advanced breast cancer. Unfortunately, the clinical benefits of an-
thracyclines are limited by cardiotoxicity that can lead to the development of poten-
tially fatal congestive heart failure. In order to limit anthracycline-related cardiotoxi-
city, liposomal formulations of doxorubicin have been developed. This retrospective
analysis evaluated the experience obtained with non-pegylated liposomal doxoru-
bicin as first-line therapy in 34 patients with metastatic breast cancer.
Methods. Patients received non-pegylated liposomal doxorubicin in combination
with either cyclophosphamide (n = 14) or docetaxel (n = 20) for up to eight cycles, and
efficacy and safety were assessed according to standard criteria.
Results.The overall response rate was 71%. The median progression-free survival was
8 months in patients receiving non-pegylated liposomal doxorubicin plus cyclophos-
phamide and 13.8 months in those receiving non-pegylated liposomal doxorubicin
plus docetaxel (P = 0.2). The most commonly observed toxicities were grade 1-2 leu-
copenia, alopecia, nausea and vomiting; no grade 3-4 toxicities were observed. Over-
all, three patients (9%) experienced grade 1 cardiac toxicity.
Conclusions. Our results support the use of non-pegylated liposomal doxorubicin as
an alternative to conventional doxorubicin formulations in combination regimens
for the first-line therapy of metastatic breast cancer.
Introduction
Anthracyclines such as doxorubicin play a central role in the management of ad-
vanced breast cancer. Treatment with anthracycline-containing regimens results in
significant improvements in response rates and time to progression, compared with
non-anthracycline regimens1-3, and approximately 20% of patients in whom a com-
plete response is achieved remain in remission after 10 years4. Combination regimens
containing anthracyclines and taxanes currently represent the most active therapies
available for advanced breast cancer, although the optimum combination in terms of
efficacy and toxicity remains to be determined5.
Unfortunately, the clinical benefits of anthracyclines are limited by cardiotoxicity
that can lead to the development of potentially fatal congestive heart failure. Where-
as this was originally outweighed by the potential benefits of treatment in patients
who were at high risk of death in the short term, the improvements in survival
achieved with modern regimens have made anthracycline cardiotoxicity a major con-
cern6. Since the cardiotoxicity is cumulative and dose-dependent7-9, it may be neces-
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sary to discontinue treatment in patients who could
otherwise continue to benefit.
In order to limit anthracycline-related cardiotoxicity,
liposomal formulations of doxorubicin have been de-
veloped. Liposomes are restricted to the vascular space
at tissues with tight capillary junctions, such as the
heart, but readily enter tissues where capillary junctions
are disrupted by tumor growth or inflammation10. As a
result, such formulations should deliver drug preferen-
tially to tumor sites, thereby reducing the risk of toxic ef-
fects in the heart11. In randomized trials, treatment with
non-pegylated liposomal doxorubicin (Myocet®,
Cephalon Inc.) in patients with metastatic breast cancer
resulted in comparable antitumor efficacy to conven-
tional formulations but was associated with significant-
ly less cardiotoxicity12-14. Furthermore, a Cochrane re-
view of these studies found that non-pegylated liposo-
mal doxorubicin was associated with a lower incidence
of other major toxicities than conventional doxoru-
bicin15.
This paper reports a retrospective analysis of our ex-
perience with non-pegylated liposomal doxorubicin,
combined with either cyclophosphamide or docetaxel,
as first-line therapy in patients with metastatic breast
cancer.
Material and methods
The study was a retrospective analysis of patients with
metastatic breast cancer receiving first-line treatment
with non-pegylated liposomal doxorubicin at a single
center in Italy.
Patients
Patients were eligible for inclusion in the analysis if
they were over 18 years of age and had confirmed
metastatic breast cancer and a Karnovsky performance
status of greater than 70%. All patients were required to
have normal bone marrow reserve (granulocytes
>2000/mm3, platelets >150,000/mm3, hemoglobin >10
g/dl), renal function (creatinine clearance >50 ml/min)
and liver function (bilirubin <2 mg/dl), and a left ven-
tricular ejection fraction (LVEF) above 50% as measured
by echography. Previous adjuvant therapy with anthra-
cyclines was allowed up to a total dose of doxorubicin
≤300 mg/m2 or epirubicin ≤450 mg/m2.
Patients were excluded if they had a history of active
angina, myocardial infarction, or other cardiovascular
disease, contraindications to the use of corticosteroids,
or active infections. Written informed consent was ob-
tained from every patient before starting treatment.
Treatment
Non-pegylated liposomal doxorubicin was given by
intravenous infusion over 1 h in combination with ei-
ther cyclophosphamide, 600 mg/m2 by intravenous in-
fusion, or docetaxel, 75 mg/m2 by intravenous infusion.
The doxorubicin dose was 50 mg/m2 when adminis-
tered with docetaxel and 60 mg/m2 when administered
with cyclophosphamide. All treatments were given on
day 1 of 21-day cycles. Patients showing a major re-
sponse or stable disease after the first three courses
continued treatment up to a maximum of eight courses;
patients with progressive disease underwent second-
line chemotherapy.
Treatment was delayed for seven days if grade 3-4
hematological toxicity were present on day 21 of any cy-
cle. Patients with grade 1 thrombocytopenia or grade 1-
2 neutropenia could receive full-dose chemotherapy
with concomitant steroids or a single dose of subcuta-
neous pegfilgrastim, 6 mg, respectively. Patients with he-
moglobin concentrations between 10 and 11 g/dl re-
ceived concomitant human erythropoietin. Chemother-
apy was delayed and supportive therapy given in pa-
tients with grade 3-4 neutropenia, grade 2-4 thrombocy-
topenia, or hemoglobin concentrations below 10 g/dl. A
dose reduction of 25% of Myocet® was provided in case
of grade 3-4 nonhematological toxicity.
Prophylactic treatment in patients receiving non-pe-
gylated liposomal doxorubicin plus docetaxel consisted
of prednisone, 25 mg, and dexchlorpheniramine
maleate, 6 mg, on the day before chemotherapy and the
day of chemotherapy, with dexamethasone, 8 mg, on
the day of treatment. Prophylaxis with HCl inhibitors
and anti-emetic treatment with 5-HT3 antagonists was
also permitted.
Assessments
Baseline assessments included a complete medical
history and physical examination, clinical laboratory
evaluation, determination of performance status score,
measurement of LVEF by echocardiography, computed
tomography of the chest and abdomen or ultrasound
imaging of the abdomen, bone scan and skeletal radi-
ographs if necessary. Complete hematological and clin-
ical chemistry evaluations, toxicity assessments, record-
ing of adverse events, and physical examination were
performed every 3 weeks, before the start of the next
treatment cycle. Cardiac ultrasound monitoring was
performed every three cycles.
Tumor response was evaluated by radiography every
three cycles. Efficacy and toxicity were evaluated ac-
cording to World Health Organization (WHO) criteria16.
The response to treatment was classified as a complete
response, partial response, or stable disease, according
to standard criteria17. The duration of response was cal-
culated as the time from the first confirmation of re-
sponse to radiologically documented progression; time
to progression was calculated as the time from the start
of treatment to the date of objectively documented pro-
gression.
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Statistical analysis
Time-to-event curves were constructed using the
Kaplan-Meier technique and compared by logrank
tests. Statistical results were considered significant at
P <0.05. All statistical tests were performed using SAS
software.
Results
A total of 34 patients were treated between February
2003 and December 2004. Of these, 20 received non-pe-
gylated liposomal doxorubicin plus docetaxel and 14 re-
ceived non-pegylated liposomal doxorubicin plus cy-
clophosphamide. Overall, in the adjuvant setting, 15 pa-
tients (44%) received hormonal therapy and 22 patients
(65%) had radiation therapy. Adjuvant chemotherapy
was administered to 50% of patients, including doxoru-
bicin in 7 patients (21%) with a median cumulative dose
of 240 mg/m2. Baseline demographic characteristics of
the patients are summarized in Table 1. All patients
were assessable for efficacy and safety.
Efficacy
The mean number of cycles per patient was 5 (range,
4-8). A total of 9 patients (64.4%) receiving non-pegylat-
ed liposomal doxorubicin plus cyclophosphamide
achieved a response, of whom 3 (21.5%) achieved a par-
tial response and 6 (42.9%) showed stable disease. In the
group receiving non-pegylated liposomal doxorubicin
plus docetaxel, 15 patients (75%) achieved a response: 7
(35%) achieved a partial response and 8 (40%) showed
stable disease. Progressive disease occurred in 5 patients
(35.6%) receiving non-pegylated liposomal doxorubicin
plus cyclophosphamide and in 5 (25%) of those receiv-
ing non-pegylated liposomal doxorubicin plus docetax-
el. The median progression-free survival was 8 months
in patients receiving non-pegylated liposomal doxoru-
bicin plus cyclophosphamide and 13.8 months in those
receiving non-pegylated liposomal doxorubicin plus do-
cetaxel. There was no significant difference in progres-
sion-free survival between the groups (P = 0.2). After a
median follow-up of 15.5 months (range, 3-46), 13 pa-
tients had died of progression of disease and 21 patients
were alive, 5 of whom were still in response.
Safety
The principal adverse events occurring during the
study are summarized in Table 2. The most commonly
observed toxicities were grade 1-2 leukopenia, alopecia,
nausea and vomiting. No grade 3-4 toxicities were ob-
served. Palmar-plantar erythrodysesthesia (hand-foot
syndrome) occurred in 2 patients (10%) receiving non-
pegylated liposomal doxorubicin plus docetaxel. In
both cases, it resolved within 2 weeks.
Overall, 3 patients (9%) developed grade 1 cardiac tox-
icity. All these patients received doxorubicin in the adju-
vant setting (240 mg/m2). No patient received adjuvant
trastuzumab and radiotherapy. One patient receiving
non-pegylated liposomal doxorubicin plus cyclophos-
phamide had an asymptomatic decrease of 15 units in
her LVEF to 50% at a doxorubicin cumulative dose of
540 mg/m2. Two patients treated with non-pegylated li-
posomal doxorubicin plus docetaxel experienced an
asymptomatic decline of resting LVEF of ≥10% but <20%
of baseline value, at a cumulative doxorubicin dose of
600 mg/m2 and 480 mg/m2, respectively.
Discussion
The results of this retrospective analysis support the
evidence from phase III randomized studies12-14 that
non-pegylated liposomal doxorubicin offers compara-
ble antitumour efficacy to conventional doxorubicin
formulations and a favorable safety profile in the first-
line therapy of metastatic breast cancer. Although no
patient experienced a complete response, the overall re-
sponse rates achieved in these patients were higher
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Table 1 - Patient characteristics
NPL doxorubicin + NPL doxorubicin +
cyclophosphamide docetaxel
n = 14 n = 20
Age (yr), mean (range) 54 (39-70) 48.2 (25-64)
Postmenopausal 7 (50) 11 (55)
Adjuvant chemotherapy 6 (43) 11 (55)
Adjuvant anthracyclines 2 (14) 5 (25)
Previous hormonal therapy 6 (43) 9 (45)
Adjuvant Radiotherapy 12 (86) 10 (50)
Right breast radiotherapy 8 (58) 8 (40)
Left breast radiotherapy 4 (28) 2 (10)
HER2 receptor status
Positive 2 (14) 3 (15)
Negative 6 (43) 9 (45)
Unknown 6 (43) 8 (40)
Estrogen receptor status
Positive 6 (43) 9 (45)
Negative 6 (43) 8 (40)
Unknown 2 (14) 3 (15)
Progesterone receptor status
Positive 5 (36) 7 (35)
Negative 7 (50) 10 (50)
Unknown 2 (14) 3 (15)
Sites of metastasis
Lung 3 (21) 4 (20)
Liver 1 (7) 3 (15)
Bone 1 (7) 2 (10)
≥2 sites 8 (58) 11 (55)
Not available 1 (7) 0 (0)
NPL, non-pegylated liposomal. In parenthesis, percentage.
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The present analysis supports the use of non-pegylated li-
posomal doxorubicin as an alternative to conventional
doxorubicin formulation in combination regimens as
first-line therapy in patients with metastatic breast cancer.
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